Summary
Twenty-eight patients with advanced or recurrent adenocarcinoma of the endometrium were treated with m-AMSA. Twenty-four patients (86%) were treated at 30 mg/M2/d × 3d q 21 d and four patients were treated at 40 mg/M2/d × 3d q 21 d intravenously. Eighty-eight courses of m-AMSA were administered with a median of 2 courses per patient. One (5%) complete response occurred in 19 patients evaluable for response. Toxicity was well tolerated and generally mild. m-AMSA may be relatively inactive in the treatment of advanced adenocarcinoma of the endometrium; further studies, however, are required to determine its effectiveness in primary previously untreated disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Donovan JF: Nonhormonal chemotherapy of endometrial adenocarcinoma: a review. Cancer 34:1587–1592, 1974
Wasserman TH, Comis RL, Goldsmith M, Handelsman H, Penta JS, Slavik M, Soper WT, Carter SK: Tabular analysis of the clinical chemotherapy of solid tumors. Cancer Chemother Rep 6:399–419, 1975
Gormley PE, Sethi VS, Cysyk RL: Interaction of 4′-(9-acri-dinyl-amino)methanesulfon-m-anisidide with DNA and inhibition of oncornavirus reverse transcriptase and cellular nucleic acid with polymerases. Cancer Res 38:1300–1306, 1978
Cain BF, Atwell GJ, Seelye RN: Potential antitumor agents. 10. Bisquaternary salts. J Med Chem 12:199–206, 1969
Cain BF, Atwell GJ: The experimental antitumor properties of three congeners of the acridylmethanesulfonanilide (AMSA) series. Eur J Cancer 10:539–549, 1974
Von Hoff DD, Howser D, Gormley P, Bender RA, Glaubiger D, Levine AS, Young RC: Phase I study of methanesulfonamide n-[4-acridinylamino)-3-methoxyphe-nyl] — (m-AMSA) using a single dose schedule. Cancer Treat Rep 62:1421–1426, 1978
Salmon SE, Meyskens FL, Alberts DS, Soehnlen B, Young L: New drugs in ovarian cancer and malignant melanoma: in vitro phase II screening with the human tumor stem cell assay. Cancer Treat Rep 65:1–12, 1981
Brenner DE, Garbino C, Kasdorf C, Villasanta U, Polcaro R, Yovarone J, Aisner J, Schiffer CA, Wiernik PH: A phase II trial of m-AMSA in the treatment of advanced gynecologic malignancies. Am J Clin Oncol 5:291–295, 1982
Ahmann FR, Meyskens FL, Moon TE, Durie BG, Salmon SE: In vitro chemosensitivities of human tumor stem cells to the phase II drug 4-(9-acridinylamino)methanesulfon-manisidide and prospective in vivo correlations. Cancer Res 42:4495–4498, 1982
De Jager R, Dupont D, Body JJ: Phase I study of oral 4′-(9-acridinylammo)methane sulfon-m-anisidide. Proc Am Soc Clin Oncol 21:146, 1980
Dombernowsky P, Hansen HH, Cavalli F: m-AMSA in advanced ovarian carcinoma — a phase II study. Proc Am Soc Clin Oncol 21:426, 1980
Hilgers RD, Legha SS, Panettiere FJ, Alberts DS: m-AMSA in epithelial carcinoma of the ovary. A Southwest Oncology Group study. Am J Clin Oncol 6:277–79, 1983
Micetich KC, Zwelling LA, Gormley P, Young RC: Phase I–II study of m-AMSA administered as a continuous infusion. Cancer Treat Rep 66:1813–1817, 1982
Schneider RJ, Woodcock TM, Howerd J, Ochoa M: Phase II trial of AMSA in previously treated patients with Stage III and IV ovarian cancer. Cancer Treat Rep 66:1589–1590, 1982
Woodcock TM, Schneider RJ, Young CW: Phase I evaluation of 4′-(9-acridinylamino) methanesulfon-m-anisidide (AMSA) by a weekly IV dose schedule. Cancer Treat Rep 64:53–55, 1980
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hilgers, R.D., Legha, S.S., Johnston, G.A. et al. m-AMSA and adenocarcinoma of the endometrium. Invest New Drugs 2, 335–338 (1984). https://doi.org/10.1007/BF00175388
Issue Date:
DOI: https://doi.org/10.1007/BF00175388